Moody's - Stock Analysis On October 25, 2018, I initiated a position in S&P Global (SPGI) within one of the ‘Side’ accounts in the FFJ Portfolio. I subsequently initiated a position in Moody's (MCO) in the same account on October 26, 2018. My rationale for having a position in both companies is: they are leading [...]
Johnson & Johnson's (JNJ) 'AAA' dividend safety makes it a candidate for investors with a low tolerance for risk who are looking for a reliable source of income. Having increased its dividend for 58 consecutive years, JNJ meets the Dividend King criteria; a Dividend King is an S&P 500 company with a market capitalization [...]
I have covered both companies in multiple posts with the most recent being: Visa (V) - July 11th and July 16thMastercard (MA) - July 12th The primary purpose of this post is to disclose the purchase of additional shares in my largest (V) and second-largest (MA) holdings. On September 2, I acquired another 50 V [...]
In my August 14th Brookfield Asset Management (BAM) stock analysis I disclose the purchase of additional BAM shares through various accounts. I conclude that post stating: 'I have no interest in investing in cryptocurrencies, SPACs, or complex derivative products. I do, however, want exposure to alternative assets thus my reason for investing in BAM.' Having [...]
Brookfield Asset Management (BAM) released Q2 and YTD results on August 12, 2021. Based on this stock analysis, I deem BAM's current valuation to be attractive. NOTE: Brookfield Asset Management is listed on the TSX (BAM-a) and the NYSE (BAM). The company is authorized to issue an unlimited number of Class A Limited Voting Shares [...]
Many investors gravitate to high-yield high-risk companies in the current low-interest-rate environment because they fixate on the dividend yield. More often than not, however, the potential reward is not commensurate with the risk being assumed and this investment approach could very well haunt these investors. Historically, high-yield high-risk companies have been susceptible to swift stock [...]
Investing in a company that develops the most successful drug to combat COVID and its variants or a company that will provide people with a means to travel into space might be exciting. Not all investors, however, seek that level of risk and excitement. In my case, I have dialled back my risk and excitement [...]
Viatris (VTRS) was formed through the combination of Mylan N.V. and Pfizer's Upjohn business. In my June 3, 2021 post, I explain my reasoning for taking a position in this company. I now revisit VTRS given the August 9 release of Q2 and YTD2021 results and guidance. Viatris - Stock Analysis - Business Overview VTRS's [...]
Intercontinental Exchange (ICE) might not be a familiar name to many investors. Most investors, however, recognize The New York Stock Exchange (NYSE); ICE purchased the NYSE as part of the NYSE Euronext acquisition in November 2013 for $11B. The NYSE, however, is just one regulated marketplace that falls within the Exchanges segment of ICE. In [...]
On June 5, 2021, I published this Vontier stock analysis in which I disclose a position within one of the 'Side' accounts in the FFJ Portfolio. This position originated by way of the Vontier (VNT) spin-off from Fortive Corporation (FTV) on October 9, 2020. Following that post, VNT: made a major acquisition announcement on July [...]
